Livestock Therapeutics & Vaccines Market Size & Share 2026-2035

Livestock Therapeutics & Vaccines Market Size

The livestock therapeutics & vaccines market was valued at USD 18.2 billion in 2025. It is projected to reach USD 19.4 billion in 2026 and USD 31.5 billion by 2035. Demand is tied to the economics of protecting productive animals rather than simply to herd expansion: disease prevention preserves output, while treatment remains necessary when prevention, biosecurity, or diagnosis fails.

Animal disease creates a material production constraint. WOAH estimates that animal diseases cause losses equivalent to about 20% of global animal production each year ^{[1]Food and Agriculture Organization of the United Nations, Climate-Smart Agriculture Sourcebook, Module B2: Livestock. fao.org}. At the same time, FAO has stated that global food production will need to increase by roughly 70% by 2050 to meet population-driven demand. These pressures make vaccines, anti-infectives, antiparasitic agents, anti-inflammatory medicines, and herd-health interventions commercially relevant inputs for food producers seeking to protect biological performance and reduce avoidable losses.

Livestock's contribution of approximately 40% to global agricultural GDP gives animal-health expenditure a direct relationship with food-system resilience ^{[2]World Organisation for Animal Health, African swine fever. woah.org}. The addressable population is extensive: FAOSTAT reports a global cattle population exceeding 1.5 billion head, while the global chicken population reached about 26.56 billion birds in 2022. The resulting demand is not uniform across species. Poultry production favors scalable flock-health programs, whereas cattle, swine, sheep, goats, and aquaculture require products suited to different disease burdens, handling practices, routes of administration, and production cycles.

The most durable commercial advantage will accrue to suppliers that make prevention practical at farm level. Product efficacy matters, but so do cold-chain compatibility, dosing convenience, integration with veterinary protocols, and fit with species-specific production systems. As disease control becomes more closely linked to trade continuity, food availability, and antimicrobial stewardship, value shifts toward solutions that reduce both biological risk and operational disruption.

Key Drivers

Infectious and transboundary disease pressure

Disease events alter producer behavior because the financial effect extends beyond animal morbidity. Outbreaks can disrupt production schedules, raise mortality risk, require movement controls, and weaken the predictability of supply. African swine fever has affected more than 50 countries across several continents, illustrating the cross-border nature of livestock disease risk ^{[3]World Health Organization, Antimicrobial resistance. who.int}. Foot-and-mouth disease is endemic in areas containing more than 77% of the global livestock population, sustaining demand for surveillance, preventive vaccination, and rapid response capacity.

The commercial consequence is a greater premium on products that fit organized disease-control programs. In markets with recurring disease threats, purchase decisions increasingly reflect a producer's need to maintain continuity of production and satisfy veterinary or regulatory requirements, rather than a one-time treatment need.

Rising demand for animal-derived food

Milk, meat, and eggs create recurring incentives to protect animal productivity. FAO reported global milk production of 965.7 million tonnes in 2023. High-output production systems have less tolerance for preventable health disruption because disease can affect feed conversion, weight gain, fertility, milk yield, and flock or herd survival. This supports demand for routine vaccination, parasite control, reproductive-health therapies, and treatments that limit the duration and economic consequences of illness.

Demand growth also changes the required delivery model. Larger and more specialized operations need products that can be incorporated into planned herd-health protocols, administered efficiently, and supported by veterinary oversight. Suppliers able to align product formats with labor availability and farm workflow have a stronger route to repeat use.

Preventive herd-health management and antimicrobial stewardship

Antimicrobial resistance is among the World Health Organization's top 10 global public-health threats ^{[4]Food and Agriculture Organization of the United Nations, Dairy Market Review. openknowledge.fao.org}. This does not eliminate demand for therapeutics, but it reinforces the incentive to prevent avoidable infections and to use treatment more selectively. Vaccination, biosecurity, diagnostics, and monitoring can reduce dependence on broad disease-response interventions when they are integrated into farm-level health plans.

The linkage between animal and human health also supports a prevention-oriented approach. WHO states that more than 60% of emerging infectious diseases in humans originate in animals. For livestock-health suppliers, this expands the relevance of products and services that improve early detection, disease reporting, and controlled use of antimicrobials.

Commercialization and intensification of livestock production

Intensive production concentrates animals, raises the consequences of disease spread, and increases the value of predictable performance. The effect is particularly visible in poultry and swine, where flock or herd-level exposure can turn a health event into a production interruption. Greater operational scale therefore supports standardized vaccination schedules, more formal veterinary engagement, and demand for formulations that reduce labor and handling requirements.

Aquaculture adds another route for market expansion. FAO reports that aquaculture supplies more than half of aquatic animals produced for human consumption. As farming systems become more commercially managed, fish-health programs can move from reactive treatment toward structured prevention, creating room for species- and production-system-specific vaccines and therapeutics.

Key Restraints

Restrictions on antimicrobial use in food animals

Antimicrobial stewardship can constrain sales of some established therapeutic products, especially where rules or buyer requirements limit routine or non-judicious use. The restraint is not merely regulatory; producers may need veterinary supervision, diagnostics, altered treatment protocols, or longer planning cycles before administering certain medicines. These changes can raise compliance costs and reduce the commercial attractiveness of undifferentiated anti-infective offerings.

The same constraint creates a portfolio challenge. Suppliers must preserve access to necessary treatments while expanding vaccines, antiparasitics, diagnostics, and alternatives that support disease prevention. Firms that cannot demonstrate responsible-use positioning may face weaker adoption in markets where food-safety scrutiny is increasing.

Stringent product approval and implementation requirements

Veterinary products must meet safety, quality, and efficacy expectations before broad commercial adoption. Approval requirements can lengthen development timelines, add evidence-generation costs, and delay the availability of products tailored to specific diseases or species. The burden can be particularly significant for novel biologics, vaccine platforms, and long-acting formulations, where manufacturing consistency and field performance must be demonstrated.

Implementation remains another constraint after approval. Veterinary capacity, cold-chain conditions, farm-management capability, and producer willingness to follow prescribed protocols influence whether a product achieves commercial scale. WOAH identifies stronger veterinary services as a core component of animal-health systems and transboundary disease control, making service infrastructure an important determinant of realized demand.

Approval complexity favors companies with the technical, regulatory, and distribution capabilities to sustain long development cycles. Smaller or narrowly positioned suppliers may still compete through local species knowledge, specialized formulations, or targeted disease expertise, but they face a higher burden when moving from a promising product concept to broad commercial use.

Livestock Therapeutics & Vaccines Market Segment Analysis

By product type

Therapeutics accounted for 60.86% of market revenue in 2025 and are projected to grow at a 5.10% CAGR through 2035. The category includes antibiotics and anti-infectives, antiparasitic agents, anti-inflammatory agents, corticosteroids, tranquilizers, cardiovascular drugs, gastrointestinal drugs, and other therapeutics. Its leading position reflects the continued need to manage active disease, parasite burdens, pain, inflammation, digestive conditions, and production-related health events across livestock systems.

Vaccines accounted for 39.14% of 2025 revenue and are projected to expand at a 6.10% CAGR. Live attenuated, inactivated, recombinant and subunit, toxoid, and other vaccine formats address different disease risks and production settings. Faster vaccine growth reflects the movement toward planned prevention, although commercial adoption remains dependent on disease epidemiology, product handling requirements, veterinary protocols, and the economic cost of an outbreak.

Recombinant and subunit approaches, vector-based technologies, and emerging mRNA platforms broaden the technological options available to vaccine developers. Their strategic importance lies in the potential to address difficult disease targets or improve product specificity, not in a guarantee of immediate commercial replacement for established vaccine types. Long-acting injectable therapeutics similarly address a practical problem: reducing repeat handling and supporting adherence where labor and animal stress are material constraints.

By animal type

Cattle represented 34.56% of the market in 2025 and are projected to grow at a 5.40% CAGR. The segment's scale is supported by global cattle numbers and by the economic importance of dairy and beef production. The 965.7 million tonnes of milk produced globally in 2023 underscores the output base exposed to mastitis, respiratory disease, parasitic infection, reproductive disorders, and other conditions that can reduce herd performance ^{[5]World Organisation for Animal Health, PVS Pathway: Improving veterinary services. woah.org}.

Poultry accounted for 26.41% of 2025 revenue and are projected to grow at a 5.90% CAGR. Large flock populations favor repeatable, scalable prevention programs, while disease events can spread rapidly under intensive production conditions. The global chicken population of approximately 26.56 billion birds in 2022 illustrates the scale at which vaccination logistics, biosecurity, and flock-level treatment decisions are made.

Swine represented 21.18% of 2025 revenue and are projected to grow at a 5.60% CAGR. African swine fever and other infectious risks make biosecurity, surveillance, and preventive disease control central purchasing considerations for producers. Sheep and goats accounted for 7.05% of 2025 revenue and are projected to advance at a 6.50% CAGR, supported by expanding preventive-health needs in small-ruminant production systems.

Aquaculture represented 8.32% of 2025 revenue and is projected to grow at a 6.20% CAGR. Fish-health products benefit from the increasing commercial importance of aquaculture, but their success depends on species biology, water conditions, stocking density, and the feasibility of administering products at scale. Other animal types accounted for the remaining 2.47% of the market and are projected to grow at a 5.20% CAGR.

By disease indication

Bacterial diseases require a balance between effective therapy and antimicrobial stewardship. The category supports demand for targeted anti-infectives, diagnostics, vaccines, and management practices that reduce disease recurrence. Viral diseases remain commercially significant because outbreaks can lead to rapid losses, restrictions on animal movement, and major preventive-vaccination requirements. Foot-and-mouth disease and African swine fever demonstrate why viral risk can shape procurement decisions across entire production systems.

Parasitic diseases sustain demand for antiparasitic agents, particularly where grazing conditions, climate, vector exposure, and resistance-management practices influence treatment frequency. Fungal diseases and other disease indications remain relevant within specialized production settings, but require disease-specific evidence and delivery approaches rather than broad portfolio assumptions.

By route of administration

Injectable, or parenteral, administration is important for vaccines, anti-infectives, antiparasitic agents, anti-inflammatory products, reproductive-health medicines, and other treatments requiring controlled dosing. Its commercial value is strongest where veterinary involvement and individual-animal handling are feasible. Long-acting injectables may reduce repeat handling, but their adoption depends on price, withdrawal requirements, farm labor, and confidence in sustained clinical performance.

Oral products are suited to situations where feed or water delivery can reach large groups efficiently, while topical products address external parasites and localized conditions. Intranasal or inhalation routes can offer disease- and species-specific administration advantages. Other routes remain relevant where anatomy, production practice, or product design requires an alternative delivery method. Route selection is therefore a commercial decision as much as a pharmacological one: the preferred option is the one that produces reliable use under real farm conditions.

By distribution channel

Veterinary hospital pharmacies held 46.01% of 2025 distribution-channel revenue and are projected to grow at a 5.10% CAGR. Their position reflects the role of veterinarians in diagnosis, prescription decisions, vaccination planning, and supervised treatment. Stronger veterinary services support animal-health systems and transboundary disease control, making this channel especially important for products requiring professional guidance ^{[6]U.S. Department of Agriculture, National Agricultural Statistics Service, Cattle. nass.usda.gov}.

Retail pharmacies accounted for 34.63% of 2025 revenue and are projected to grow at a 5.70% CAGR. Their relevance is tied to local access for routine products and repeat purchases. E-commerce represented 13.28% of 2025 revenue and is projected to expand at a 5.40% CAGR, but its development depends on product regulation, fulfillment capability, cold-chain needs, and the extent to which veterinary authorization is required. Other distribution channels accounted for 6.07% of revenue and are projected to grow at a 4.90% CAGR.

Vaccines are gaining relative momentum because prevention addresses the economic and regulatory consequences of disease before they occur. Yet the therapeutic category remains larger because livestock health is not managed in a fully preventive environment. The winning portfolio is therefore not a binary choice between treatment and prevention; it is an integrated offering that supports diagnosis, routine protection, targeted intervention, and responsible antimicrobial use.

Livestock Therapeutics & Vaccines Market Regional Analysis

North America accounted for 40.01% of global market revenue in 2025 and is projected to grow at a 5.45% CAGR through 2035. The regional market is expected to increase from USD 7,270.0 million in 2025 to USD 9,709.7 million in 2030 and USD 12,334.4 million in 2035. Large-scale production systems, formal veterinary channels, and disease-control requirements support demand for both vaccines and therapeutics.

The United States represented 91.11% of North American revenue in 2025 and is projected to grow at a 5.70% CAGR, while Canada accounted for 8.89% and is projected to grow at a 6.30% CAGR. USDA reported a U.S. cattle and calves inventory of 86.7 million head as of January 1, 2025 ^{[7]Eurostat, Agricultural production: livestock and meat. ec.europa.eu}. In North America, veterinary hospital pharmacies represented 46.01% of 2025 distribution-channel revenue, ahead of retail pharmacies at 34.63%, e-commerce at 13.28%, and other channels at 6.07%.

Europe represented 26.20% of global revenue in 2025 and is projected to grow at a 5.60% CAGR. The region's livestock base supports a broad demand profile across cattle, swine, poultry, and small ruminants, while its regulatory environment reinforces preventive health management and responsible medicine use. Eurostat reported that the European Union had 132 million pigs, 72 million bovine animals, and 67 million sheep and goats in 2024.

Germany remains an important European market because of its cattle, swine, and poultry production base. Destatis reported approximately 10.5 million cattle in Germany in 2024. The United Kingdom, France, Spain, Italy, and the Netherlands add distinct demand patterns shaped by their respective livestock mixes, veterinary practices, animal-welfare expectations, and disease-control frameworks.

Asia Pacific accounted for 22.09% of global market revenue in 2025 and is projected to post the fastest regional CAGR, at 6.20%. China, Japan, India, Australia, and South Korea provide different growth conditions, ranging from large-scale protein production and expanding disease-control programs to established veterinary infrastructures and specialized livestock systems. China produced approximately 96.63 million tonnes of meat in 2024, demonstrating the scale of the country's food-animal production base.

Asia Pacific's growth potential rests on more than animal numbers. Producers are increasingly required to manage disease risk alongside food-security objectives, commercial farm expansion, and changing animal-health practices. This creates demand for scalable vaccination programs, veterinary diagnostics, biosecurity support, and treatment protocols adapted to local production systems.

Latin America represented 7.81% of global revenue in 2025 and is projected to grow at a 5.90% CAGR. Brazil is central to the region's livestock-health demand. Its cattle herd reached approximately 238.6 million head in 2023, the largest in the country's recorded history. The size of this production base increases the strategic importance of preventive disease management, parasite control, reproductive health, and veterinary services. Mexico and Argentina broaden the regional opportunity through their own cattle, poultry, and swine production systems.

The Middle East and Africa accounted for 3.89% of global market revenue in 2025 and are projected to grow at a 5.10% CAGR. Demand is shaped by food-security priorities, uneven veterinary-service capacity, disease-surveillance needs, and the large role of small-ruminant production in several markets. Saudi Arabia's livestock population exceeded 22 million head in 2023, with sheep and goats accounting for the majority. South Africa and the United Arab Emirates add different commercial conditions, reflecting their production structures, import exposure, and animal-health infrastructure.

Latin America and the Middle East and Africa demonstrate why livestock population alone is not the same as market maturity. Brazil's record cattle herd creates a substantial need for herd-health solutions, while Saudi Arabia's small-ruminant-heavy livestock base calls for products and distribution models tailored to its species mix. Suppliers that localize disease priorities, administration methods, and channel strategy are better positioned than those relying on a single global portfolio model.

Livestock Therapeutics & Vaccines Market Share & Competitive Landscape

Competition involves a mix of multinational animal-health companies and specialized suppliers serving different product, species, and regional requirements. The competitive set comprises Zoetis; Merck Animal Health (MSD Animal Health); Boehringer Ingelheim Animal Health; Elanco Animal Health; Ceva Santé Animale; Virbac; HIPRA; Vetoquinol; Phibro Animal Health; Indian Immunologicals; Vaxxinova; Biogénesis Bagó; Bioveta; Neogen Corporation; and Norbrook.

Competitive differentiation depends on the ability to combine product development with reliable commercialization. Vaccine suppliers must manage disease specificity, manufacturing quality, field delivery, and regulatory evidence. Therapeutic suppliers face parallel demands around efficacy, responsible use, product availability, administration convenience, and fit with veterinary protocols. As antimicrobial stewardship increases the value of prevention, companies with both vaccine and therapeutic capabilities can position their offerings around a broader herd-health pathway rather than a single treatment event.

Technology is becoming an additional source of differentiation. Recombinant and subunit vaccines, vector-based approaches, long-acting injectable formulations, diagnostics, digital livestock-health monitoring, genomics-based surveillance, precision veterinary medicine, emerging mRNA platforms, and monoclonal antibodies may alter development priorities and customer expectations. Commercial uptake will depend on demonstrable field value, regulatory acceptance, practical administration, and economics at farm level.

Recent Industry Developments

On January 16, 2025, Ceva Animal Health and Touchlight signed a licensing and collaboration agreement granting Ceva rights to develop and manufacture animal health products using Touchlight's doggybone DNA (dbDNA™) technology. The program covers dbDNA-based vaccines and therapeutics across a broad range of animal health indications, with commercial terms including an upfront payment, development milestones, and royalties on sales of commercialized products. Ceva, already the first company to have launched an RNA vaccine for avian influenza, aims to use the platform to extend its nucleic-acid-vaccine pipeline using a manufacturing process that eliminates antibiotic-resistance genes and does not require plasmid-based production.

In 2025, Vaxxinova received USDA authorization to import Vaxxon® SHS, a live attenuated avian metapneumovirus (aMPV) vaccine for poultry, under a Veterinary Biological Product Permit - the first such US authorization for importation of a live vaccine for food-producing animals. The vaccine, established in international poultry production systems for more than 20 years, was made available to US turkey and poultry producers responding to active aMPV outbreaks through close collaboration with the National Turkey Federation and regulatory authorities. Vaxxon® SHS also enables a live-vaccine priming and inactivated-boost strategy when combined with Vaxxinova's autogenous aMPV vaccine.

On February 25, 2025, Elanco Animal Health and South Dakota-based Medgene announced a commercialization agreement to advance Medgene's H5N1 (highly pathogenic avian influenza) vaccine for dairy cattle in the United States. Medgene's vaccine met USDA platform-technology-guideline requirements and was in the final stages of review for conditional license approval at the time of the announcement. The agreement addresses an outbreak that had spread to nearly 1,000 US dairy herds since March 2024 and had also recorded zoonotic transmission to humans, with Elanco describing the product as a future component of routine vaccination protocol for the US dairy industry.